表紙:高リン血症:パイプライン製品の分析
市場調査レポート
商品コード
950842

高リン血症:パイプライン製品の分析

Hyperphosphatemia - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 80 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.87円
高リン血症:パイプライン製品の分析
出版日: 2020年06月30日
発行: Global Markets Direct
ページ情報: 英文 80 Pages
納期: 即納可能 即納可能とは
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

高リン酸血症、すなわち、異常に高い血清リン酸塩レベルは、リン酸塩摂取量の増加、リン酸塩排泄の減少、または細胞内リン酸塩を細胞外空間にシフトさせる障害に起因する可能性があります。この状態は、慢性腎臓病の患者に最もよく見られます。兆候と症状には、疲労、吐き気、睡眠障害、息切れ、骨と関節の痛み、そう痒症、発疹があります。治療には、リン酸塩結合剤と利尿薬を用います。

当レポートでは、高リン血症を標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

目次

目次

表一覧

図一覧

  • イントロダクション
  • 調査範囲
  • 高リン血症-概要
  • 高リン血症-治療薬の開発
  • パイプラインの概要
  • 企業別パイプライン
  • 大学/機関別パイプライン
  • 企業が開発中の製品
  • 大学・研究機関が開発中の製品
  • 高リン血症-治療評価
  • ターゲット別評価
  • 作用機序別評価
  • 投与経路別評価
  • 分子タイプ別評価
  • 高リン血症-治療薬開発に関与する企業
  • 3SBio Inc
  • Ardelyx Inc
  • China Nuokang Bio-Pharmaceutical Inc
  • 中外製薬
  • Citragen Pharmaceuticals Inc
  • J-Pharma Co Ltd
  • OPKO Health Inc
  • Panion&Bf Biotech Inc
  • Shield Therapeutics Plc
  • Unicycive Therapeutics Inc
  • Vidasym Inc
  • 高リン血症-薬物プロファイル
  • CGN-002-薬物プロファイル
  • 製品説明
  • 作用機序
  • 研究開発の進捗状況
  • コレスチラン塩化物-薬物プロファイル
  • 製品説明
  • 作用機序
  • 研究開発の進捗状況
  • EOS-789-薬物プロファイル
  • 製品説明
  • 作用機序
  • 研究開発の進捗状況
  • fermagate-薬物プロファイル
  • 製品説明
  • 作用機序
  • 研究開発の進捗状況
  • クエン酸第二鉄-薬物プロファイル
  • 製品説明
  • 作用機序
  • 研究開発の進捗状況
  • JPH-101-薬物プロファイル
  • 製品説明
  • 作用機序
  • 研究開発の進捗状況
  • ポリスチレンスルホン酸ランタン-薬物プロファイル
  • 製品説明
  • 作用機序
  • 研究開発の進捗状況
  • PT-20-薬物プロファイル
  • 製品説明
  • 作用機序
  • 研究開発の進捗状況
  • 高リン血症の小分子-薬物プロファイル
  • 製品説明
  • 作用機序
  • 研究開発の進捗状況
  • Tenapanor塩酸塩-薬物プロファイル
  • 製品説明
  • 作用機序
  • 研究開発の進捗状況
  • UNI-494-薬物プロファイル
  • 製品説明
  • 作用機序
  • 研究開発の進捗状況
  • VS-501-薬物プロファイル
  • 製品説明
  • 作用機序
  • 研究開発の進捗状況
  • 高リン血症-休眠プロジェクト
  • 高リン血症-製造中止製品
  • 高リン血症-製品開発のマイルストーン
  • 注目のニュースとプレスリリース
  • 2020年6月15日:Ardelyxは、透析中のCKD患者におけるTenapanorを評価する進行中のNORMALIZEフェーズ4研究からの肯定的な2番目のデータ分析を発表
  • 2019年12月4日:ArdelyxがTenapanorの第III相CKD試験の肯定的なデータを報告
  • 2019年11月6日:ArdelyxがKidney Week 2019でのプレゼンテーションを発表
  • 2019年10月15日:AkebiaがCMSを告訴:FDA承認のAuryxiaの鉄欠乏性貧血の適応症のメディケアパートDの適応範囲を2018年に廃止し、高リン血症の適応症に対する事前の承認要件を課すことに対して
  • 2019年9月3日:Ardelyxは、リン酸塩結合剤治療にもかかわらず制御不良の高リン血症を有する透析患者におけるTenapanorを評価する重要な第3相AMPLIFY研究の肯定的な結果を発表しました
  • 2019年3月7日:Ardelyxは、米国腎学会誌で高リン血症の治療のためのTenapanorの肯定的な第III相の結果の査読済み論文を発表
  • 2019年2月7日:Ardelyxのコラボレーションパートナーである協和発酵キリンが、日本で透析中の高リン血症患者を対象としたTenapanorの第Ⅱ相臨床試験の開始を発表
  • 2018年10月26日:Ardelyxは、血清リンの上昇のためにTenapanorとセベラマーを組み合わせて投与した場合の相乗効果を示す新しい前臨床データを発表
  • 2018年8月29日:Ardelyxは、傍細胞のリン酸吸収を阻害するTenapanorのユニークな作用機序を詳しく説明するScience Translational Medicineの出版を発表
  • 2018年5月21日:ArdelyxがSolar Capital およびBridge Bankとの融資契約で5,000万米ドルを調達
  • 2017年11月21日:ArdelyxがTenapanorの更新開発経路を発表
  • 2017年4月18日:Ardelyxが今後の春の医療会議でTenapanorを発表
  • 2017年2月15日:Ardelyxが末期腎疾患患者の高リン血症に対するTenapanorの第Ⅲ相試験の成功を発表
  • 2017年1月6日:Shield TherapeuticsがPT20のアップデートを提供
  • 2016年10月14日:Keryx Biopharmaceuticalsは、米国腎臓学会腎臓週2016年次総会でのデータのプレゼンテーションを発表
  • 付録
  • 調査方法
  • 調査範囲
  • 2次調査
  • 1次調査
  • 専門家パネル検証
  • お問い合わせ
  • 免責事項
図表

List of Tables

List of Tables

  • Number of Products under Development for Hyperphosphatemia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Hyperphosphatemia - Pipeline by 3SBio Inc, H1 2020
  • Hyperphosphatemia - Pipeline by Ardelyx Inc, H1 2020
  • Hyperphosphatemia - Pipeline by China Nuokang Bio-Pharmaceutical Inc, H1 2020
  • Hyperphosphatemia - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
  • Hyperphosphatemia - Pipeline by Citragen Pharmaceuticals Inc, H1 2020
  • Hyperphosphatemia - Pipeline by J-Pharma Co Ltd, H1 2020
  • Hyperphosphatemia - Pipeline by OPKO Health Inc, H1 2020
  • Hyperphosphatemia - Pipeline by Panion & Bf Biotech Inc, H1 2020
  • Hyperphosphatemia - Pipeline by Shield Therapeutics Plc, H1 2020
  • Hyperphosphatemia - Pipeline by Unicycive Therapeutics Inc, H1 2020
  • Hyperphosphatemia - Pipeline by Vidasym Inc, H1 2020
  • Hyperphosphatemia - Dormant Projects, H1 2020
  • Hyperphosphatemia - Discontinued Products, H1 2020

List of Figures

List of Figures

  • Number of Products under Development for Hyperphosphatemia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12323IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia - Pipeline Review, H1 2020, provides an overview of the Hyperphosphatemia (Nutritional Disorders) pipeline landscape.

Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperphosphatemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hyperphosphatemia (Nutritional Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperphosphatemia (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 1, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hyperphosphatemia (Nutritional Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperphosphatemia (Nutritional Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hyperphosphatemia (Nutritional Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperphosphatemia (Nutritional Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperphosphatemia (Nutritional Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperphosphatemia (Nutritional Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperphosphatemia (Nutritional Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperphosphatemia (Nutritional Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hyperphosphatemia - Overview
  • Hyperphosphatemia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Hyperphosphatemia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Hyperphosphatemia - Companies Involved in Therapeutics Development
  • 3SBio Inc
  • Ardelyx Inc
  • China Nuokang Bio-Pharmaceutical Inc
  • Chugai Pharmaceutical Co Ltd
  • Citragen Pharmaceuticals Inc
  • J-Pharma Co Ltd
  • OPKO Health Inc
  • Panion & Bf Biotech Inc
  • Shield Therapeutics Plc
  • Unicycive Therapeutics Inc
  • Vidasym Inc
  • Hyperphosphatemia - Drug Profiles
  • CGN-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • colestilan chloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EOS-789 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fermagate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ferric citrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JPH-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lanthanum polystyrene sulfonate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PT-20 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Hyperphosphatemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tenapanor hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • UNI-494 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VS-501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Hyperphosphatemia - Dormant Projects
  • Hyperphosphatemia - Discontinued Products
  • Hyperphosphatemia - Product Development Milestones
  • Featured News & Press Releases
  • Jun 15, 2020: Ardelyx announces positive second data analysis from ongoing NORMALIZE phase 4 study evaluating Tenapanor in CKD patients on dialysis
  • Dec 04, 2019: Ardelyx reports positive data from tenapanor's Phase III CKD trial
  • Nov 06, 2019: Ardelyx announces presentation at Kidney Week 2019
  • Oct 15, 2019: Akebia files lawsuit against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia for its Iron Deficiency Anemia Indication and imposing a prior authorization requirement for its Hyperphosphatemia indication
  • Sep 03, 2019: Ardelyx announces positive results from the pivotal phase 3 AMPLIFY study evaluating tenapanor in dialysis patients who have uncontrolled hyperphosphatemia despite phosphate binder treatment
  • Mar 07, 2019: Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
  • Feb 07, 2019: Ardelyx collaboration partner, Kyowa Hakko Kirin, announces initiation of a phase 2 clinical study of Tenapanor for Hyperphosphatemia patients on dialysis in Japan
  • Oct 26, 2018: Ardelyx presents new preclinical data demonstrating synergy between Tenapanor and Sevelamer when dosed in combination for elevated serum phosphorus
  • Aug 29, 2018: Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
  • May 21, 2018: Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank
  • Nov 21, 2017: Ardelyx Announces Updated Development Path for Tenapanor
  • Apr 18, 2017: Ardelyx To Present Tenapanor at Upcoming Spring Medical Meetings
  • Feb 15, 2017: Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
  • Jan 06, 2017: Shield Therapeutics Provides Update on PT20
  • Oct 14, 2016: Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer